Incyte Corp
NASDAQ:INCY
Incyte Corp
NASDAQ:INCY
Price:
57.79 USD
0.86%
Market Closed
Updated:
Jun 1, 2024
Incyte Corp
Accrued Liabilities
|
Incyte Corp
Accrued Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Accrued Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Incyte Corp
NASDAQ:INCY
|
Accrued Liabilities
$767.5m
|
CAGR 3-Years
34%
|
CAGR 5-Years
37%
|
CAGR 10-Years
26%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$5.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
$14.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$2.8B
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
28%
|
See Also
What is Incyte Corp's Accrued Liabilities?
Accrued Liabilities
767.5m
USD
767.5m
USD
Based on the financial report for Mar 31, 2024, Incyte Corp's Accrued Liabilities amounts to 767.5m USD.
What is Incyte Corp's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
26%
26%
Over the last year, the Accrued Liabilities growth was 37%. The average annual Accrued Liabilities growth rates for Incyte Corp have been 34% over the past three years , 37% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet
